Cytochrome P450 polymorphisms in patients with Behcet's disease

International Journal of Dermatology

Volumn 46, Issue 2, 2007, Pages 153-156

  Tursen, Umit ^a,b   Tamer, Lulufer ^a   Api, Hale ^a   Yildirim, Hatice ^a   Baz, Kiymet ^a   Ikizoglu, Guliz ^a   Atik, Ugur ^a  

^a MERSIN UNIVERSITY   (Turkey)

^b MERSIN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; WILD TYPE;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BEHCET SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 34247632129     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.02957.x     Document Type: Article

References (17)

1. Behçet H. Uber rezidivierende aphthouse durch ein virus verursachte Geschwuere am Mund, am Auge und an den Genitalien. Dermatol Monatsschr Wochenschr 1937; 105: 1152-1157.
2. Gurler A, Boyvat A, Tursen U. Clinical manifestations of Behçet's disease; analysis 2147 patients. Yonsei Med J 1997; 38: 423-427.
3. Niwa Y, Miyake S, Sakane T, et al. Auto-oxidative damage in Behçet's disease-endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 1982; 49: 247-255.
4. O'Duffy JD. Behcet's disease. Curr Opin Rheumatol 1994; 6: 39-43.
5. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 2003; 35: 99-106.
6. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285-299.
7. McKinnon RA, Nebert DW. Possible role of cytochromes P450 in lupus erythematosus a related disorders. Lupus 1994; 3: 473-478.
8. Povey A, Guppy MJ, Wood M, et al. Cytochrome P2 polymorphisms and susceptibility to scleroderma following exposure to organic solvents. Arth Rheum 2001; 44: 662-665.
9. Akdeniz N, Esrefoglu M, Keles MS, et al. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease. Ann Acad Med Singap 2004; 33: 596-599.
10. Frye RF, Schneider VM, Frye CS, et al. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail 2002; 8: 315-319.
11. Yen JH, Tsai WC, Lin CH, et al. Cytochrome P450 ΙAΙ and manganese superoxide dismutase gene polymorphisms in Behcet's disease. J Rheumatol 2004; 31: 736-740.
12. International Study Group for Behçet's Disease Contributors. Evaluation of diagnostic ("classification") criteria in Behçet's disease: Toward internationally agreed criteria. In: O'Duffy JD, Kökmen E, eds. Behçet's Disease Basic and Clinical Aspects. New York: Marcel Dekker Inc., 1991: 11-39.
13. Kose K, Yazici C, Cambay N, et al. Lipid peroxidation and erythrocyte antioxidant enzymes in patients with Behcet's disease. Tohoku J Exp Med 2002; 197: 9-16.
14. Taysi S, Kocer I, Memisogullari R, Kiziltunc A. Serum oxidant/ antioxidant status in patients with Behcet's disease. Ann Clin Lab Sci 2002; 32: 377-382.
15. Aynacioglu AS, Bozkurt A, Nacak M, et al. N-acetyltransferase polymorphism in patients with Behcet's disease. Eur J Clin Pharmacol 2001; 57: 659-662.
16. Emmi L, Brugnolo F, Marchione T. Pathogenesis and therapy of Behçet's disease. Ann Ital Med Int 1997; 12: 20-25.
17. Freitas JP, Filipe P, Yousefi A, et al. Oxidative stress in Adamantiades-Behcet's disease. Dermatology 1998; 197: 343-348.